Bloom Science

Bloom Science is developing a new class of gut-brain axis therapeutics, with a lead candidate designed to mimic the ketogenic diet's effects without its restrictive regimen. The company has reported positive Phase 1 data for BL-001 in obesity and is planning Phase 2 trials in both obesity and Dravet syndrome, a severe form of epilepsy. Its proprietary IrisRx™ platform integrates synthetic biology and a microbial knowledgebase to engineer commensal bacteria for broad therapeutic potential. As a private, pre-revenue company, Bloom is positioning itself in the competitive but high-growth microbiome and metabolic health spaces.

IrisRx™ discovery platform: a proprietary system integrating bioinformatics, microbiology, and synthetic biology with a knowledgebase of gut commensal microbes to identify and engineer bacterial strains for multi-pathway therapeutics targeting the gut-brain axis.

In obesity, Bloom faces intense competition from established and next-generation GLP-1 and multi-agonist drugs from Novo Nordisk, Eli Lilly, and others. In Dravet syndrome, it competes with other anti-seizure medications and the standard ketogenic diet. As a microbiome-gut-brain axis therapeutic, it competes with other early-stage biotechs like Axial Therapeutics, Kallyope, and Vedanta Biosciences, though each has a distinct technological approach.